Welcome to InvestSMART

You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:

General Information

Antisense Therapeutics Limited
ANP
http://www.antisense.com.au
Pharmaceuticals
24
161

Current Price Data+

Current Price Open High Low Last Close Volume Price Movement
$0.15 $0.17 $0.17 $0.15 $0.17 501419 $0.02 ( 9.09% )
  • +Security prices are delayed by least 20 minutes and are indicative only.

Company Overview

Business Description
Antisense Therapeutics Limited (ANP) is a biopharmaceutical drug discovery and development company. ANP develops and commercialises second generation antisense pharmaceuticals for large unmet markets. ANP has four products including ATL1102 injection for Multiple Sclerosis, ATL1103 injection for growth & sight disorders, ATL1101 injection for prostate cancer, and ATL1102 inhaled for asthma.
Strategy Analysis
--

Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2014 A -3.0 -2.1 0.0% 0.0 0.0 0.0% 0.0%
2013 A -2.5 -1.7 0.0% 0.0 0.0 0.0% 0.0%
2012 A -1.8 -1.8 0.0% 0.0 0.0 0.0% 0.0%

Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2012 A 2013 F 2014 F 2012 A 2013 F 2014 F 2012 A 2013 F 2014 F
Acrux Limited (ACR) $146M 3.0384 -0.6054 0.2338 5.2083 13.1976 10.6968 9.14% 8.78% 8.64%
Antisense Therapeutics (ANP) $27M 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Mayne Pharma Group (MYX) $896M 1.0457 -0.2428 1.2152 36.4217 48.1013 21.7143 0.00% 0.00% 0.00%

Financial Summary

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 10.34 0.00
Market 1.03 14.40 1.04 1.07
Sector 0.87 11.70 2.74 1.40

Directors

Name Position Start Date
Mr Robert William Moses Chairman 23/10/2001
Mr Mark P Diamond Chief Executive Officer, Managing Director 31/10/2001
Dr Christopher (Chris) Belyea Non-Executive Director 13/11/2000
Professor Graham Mitchell Non-Executive Director 24/10/2001

Management

Name Position
Phillip Hains Chief Financial Officer, Company Secretary

Substantial Shareholders

Holding Name
143,149,187 (9.93%) Polychip Pharmaceuticals Pty Ltd

Calendar of Events

Date Event
24 February 2016 Report (Interim)
05 October 2015 Report (Annual)
24 August 2015 Report (Prelim)
© 2011 Morningstar, Inc. All rights reserved. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for use or distribution of any of this information. To the extent that any of the content above constitutes advice, it is general advice that has been prepared by Morningstar Australasia Pty Ltd ABN: 95 090 665 544, AFSL: 240892 (a subsidiary of Morningstar, Inc.), without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain financial, legal and taxation advice before making any financial investment decision. If applicable investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). DISCLOSURE: Employees may have an interest in the securities discussed in this report. Please refer to our Financial Services Guide (FSG) for more information at www.morningstar.com.au/fsg.asp.